Showing 4431-4440 of 5646 results for "".
- Schwind Receives “SME Innovation Award“ in Germanyhttps://modernod.com/news/schwind-receives-sme-innovation-award-in-germany/2479288/Schwind eye-tech-solutions is one of the most innovative small and medium sized enterprises (SMEs) 2021/2022, according to a survey conducted by the independent Deutsche Gesellschaft für Verbraucherstudien (DtGV) in
- US to Buy 500 Million Doses of Pfizer, BioNTech COVID-19 Vaccine for Donation to Poorest Nationshttps://modernod.com/news/us-to-buy-500-million-doses-of-pfizer-biontech-covid-19-vaccine-for-donation-to-poorest-nations/2479284/Pfizer and BioNTech said Thursday that they will provide 500 million doses of the COVID-19 vaccine BNT162b2 to the US government at a not-for-profit price to support immunization programs in low- and lower-middle-income countries, according to FirstWord. The companies noted that 200 million doses
- Iveric Bio to Host Investor Symposium on Dry AMDhttps://modernod.com/news/iveric-bio-to-host-investor-symposium-on-dry-amd/2479282/Iveric bio announced details for its Dry Age-Related Macular Degeneration Virtual Symposium for investors and analysts being held on Friday, June 18, 2021 from 10 am to 12 pm Eastern Time. The symposium will include presentations on the company’s Zimura (avacincaptad pegol) pivotal program in geo
- Oyster Point Pharma Announces Collaboration with Adaptive Phage Therapeutics to Target Ophthalmic Diseaseshttps://modernod.com/news/oyster-point-pharma-announces-collaboration-with-adaptive-phage-therapeutics-to-target-ophthalmic-diseases/2479281/Oyster Point Pharma announced a newly formed research collaboration with Adaptive Phage Therapeutics (APT) to leverage APT’s PhageBank technology for the development of potential treatments for multiple ophthalmic diseases. APT’s PhageBank technology is engi
- EyeYon Medical Receives CE Mark for its EndoArt Implant to Treat Chronic Corneal Edemahttps://modernod.com/news/eyeyon-medical-receives-ce-mark-for-its-endoart-implant-to-treat-chronic-corneal-edema/2479277/EyeYon Medical announced that it has received CE Mark for its EndoArt after clinical trials demonstrated safety and efficacy for treating chronic corneal edema. EyeYon says the EndoArt is the world’s first and only synthetic implant that replaces the human endothelium that the human
- International Sports Vision Association and Macuhealth Offer New Educational Resource on Sports Nutrition for Your Eyeshttps://modernod.com/news/international-sports-vision-association-and-macuhealth-offer-new-educational-resource-on-sports-nutrition-for-your-eyes/2479270/The International Sports Vision Association (ISVA) and MacuHealth announced the launch of “Sports Nutrition for Your Eyes,” a new educational resource on the ISVA website designed to help educate athletes about how proper nutrition ca
- Oxular Appoints Dr. Friedrich Asmus as Chief Medical Officerhttps://modernod.com/news/oxular-appoints-dr-friedrich-asmus-as-chief-medical-officer/2479267/Oxular Limited announced it has appointed Friedrich (Fritz) Asmus, MD, as Chief Medical Officer. Dr. Asmus will lead all medical, clinical, and regulatory functions to further the company’s lead asset, OXU‑001, for the treatment of diabetic macular edema (DME), and to accelerate the development o
- High Caffeine Consumption May Be Associated With Increased Risk of Glaucomahttps://modernod.com/news/high-caffeine-consumption-may-be-associated-with-increased-risk-of-blinding-eye-disease/2479268/Consuming large amounts of daily caffeine may increase the risk of glaucoma more than three-fold for those with a genetic predisposition to higher eye pressure, according to an international multicenter study. The research led by the Icahn School of Medicine at Mount Sinai is the first to demonst
- Lighthouse Guild Starts Construction on New Technology Centerhttps://modernod.com/news/lighthouse-guild-starts-construction-on-new-technology-center/2479265/Lighthouse Guild has started construction on a Technology Center that will be the largest, premier assistive technology resource in the United States, according to a news release. Designed for people who are visually impaired and for all people who are using technology in order to help them, it i
- Avellino Launches AvaGen as First Genetic Test to Quantify Keratoconus Risk and Presence of Corneal Dystrophieshttps://modernod.com/news/avellino-launches-avagen-as-first-genetic-test-to-quantify-keratoconus-risk-and-presence-of-corneal-dystrophies/2479255/Avellino Lab USA announced full nationwide availability in the US of AvaGen, as the first genetic test that helps determine a patient’s risk of keratoconus and the presence of other corneal dystrophies. The test allows for more confident management and treatment for patients with these conditions